Skip to main content
ACR Convergence 2025 Main banner
Final Program


Schedule at a Glance
Legend
Presentation Icons
CME
CME
Non-CME
Non-CME
In Person
In Person
On Demand
On Demand
Live Stream
Live Stream
Active Learning
Active Learning
Choose Rheum
Choose Rheum
Emerging Investigator Awardee
Emerging Investigator Awardee

Sofia Ramiro, MD, PhD

Leiden University Medical Center
Bunde, Netherlands

Sofia Ramiro, MD, PhD, is a rheumatologist and a senior researcher at Leiden University Medical Center and Zuyderland Medical Center, the Netherlands. Dr Ramiro graduated from Medical School in the Nova Medical School, New University of Lisbon, Portugal. She completed a Master's in Epidemiology at Maastricht University and obtained her PhD on long-term outcomes in axial spondyloarthritis at the University of Amsterdam. She is a clinical epidemiologist and her research focuses in axial spondyloarthritis (axSpA), rheumatoid arthritis (RA), imaging and outcomes research.
Dr Ramiro currently has an appointment at Nova Medical School in Lisbon as a Visiting Professor. She served as a Chair for EMEUNET, the Emerging European League against Rheumatism (EULAR) Network. She was a member of the EULAR Scientific Committee for 4 years and is a member of the ASAS Executive Committee. Dr Ramiro has been involved in many EULAR taskforces for the elaboration of recommendations, namely management of axSpA, RA, psoriatic arthritis, and imaging in vasculitis. Sofia Ramiro has authored more than 290 peer-reviewed manuscripts.

Presentation(s):

  • 0589: Comparing Efficacy of Upadacitinib in Male and Female Patients with axSpA: Results from the SELECT-AXIS 1 and 2 Trials

    Sunday, October 26, 2025
    10:30 AM - 12:30 PM Central Time

    Disclosure(s): AbbVie/Abbott: Consultant (Ongoing), Grant/Research Support (Ongoing); Alfasigma: Consultant (Ongoing), Grant/Research Support (Ongoing); Eli Lilly: Consultant (Ongoing), Grant/Research Support (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Johnson & Johnson: Consultant (Ongoing); Merck/MSD: Consultant (Ongoing); Novartis: Consultant (Ongoing), Grant/Research Support (Ongoing); Pfizer: Consultant (Ongoing), Grant/Research Support (Ongoing); UCB: Consultant (Ongoing), Grant/Research Support (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing)

  • 0588: The effect of biological and targeted synthetic DMARDs on peripheral manifestations in axial spondyloarthritis: a systematic literature review

    Sunday, October 26, 2025
    10:30 AM - 12:30 PM Central Time

    Disclosure(s): AbbVie/Abbott: Consultant (Ongoing), Grant/Research Support (Ongoing); Alfasigma: Consultant (Ongoing), Grant/Research Support (Ongoing); Eli Lilly: Consultant (Ongoing), Grant/Research Support (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Johnson & Johnson: Consultant (Ongoing); Merck/MSD: Consultant (Ongoing); Novartis: Consultant (Ongoing), Grant/Research Support (Ongoing); Pfizer: Consultant (Ongoing), Grant/Research Support (Ongoing); UCB: Consultant (Ongoing), Grant/Research Support (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing)

  • 1324: Similar Negative Effects of Fatigue on Physical Activity in Persons with Rheumatoid Arthritis and Healthy Controls: A Patient-Control Study

    Monday, October 27, 2025
    10:30 AM - 12:30 PM Central Time

    Disclosure(s): AbbVie/Abbott: Consultant (Ongoing), Grant/Research Support (Ongoing); Alfasigma: Consultant (Ongoing), Grant/Research Support (Ongoing); Eli Lilly: Consultant (Ongoing), Grant/Research Support (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Johnson & Johnson: Consultant (Ongoing); Merck/MSD: Consultant (Ongoing); Novartis: Consultant (Ongoing), Grant/Research Support (Ongoing); Pfizer: Consultant (Ongoing), Grant/Research Support (Ongoing); UCB: Consultant (Ongoing), Grant/Research Support (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing)

  • 2331: Coping with Rheumatic Stressors in Axial Spondyloarthritis: Association with Patient Characteristics and Disease Phenotypes and Changes Over Time

    Tuesday, October 28, 2025
    10:30 AM - 12:30 PM Central Time

    Disclosure(s): AbbVie/Abbott: Consultant (Ongoing), Grant/Research Support (Ongoing); Alfasigma: Consultant (Ongoing), Grant/Research Support (Ongoing); Eli Lilly: Consultant (Ongoing), Grant/Research Support (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Johnson & Johnson: Consultant (Ongoing); Merck/MSD: Consultant (Ongoing); Novartis: Consultant (Ongoing), Grant/Research Support (Ongoing); Pfizer: Consultant (Ongoing), Grant/Research Support (Ongoing); UCB: Consultant (Ongoing), Grant/Research Support (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing)

  • 2334: Development and validation analysis of a Corrected Axial Spondyloarthritis Metrology Index

    Tuesday, October 28, 2025
    10:30 AM - 12:30 PM Central Time

    Disclosure(s): AbbVie/Abbott: Consultant (Ongoing), Grant/Research Support (Ongoing); Alfasigma: Consultant (Ongoing), Grant/Research Support (Ongoing); Eli Lilly: Consultant (Ongoing), Grant/Research Support (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Johnson & Johnson: Consultant (Ongoing); Merck/MSD: Consultant (Ongoing); Novartis: Consultant (Ongoing), Grant/Research Support (Ongoing); Pfizer: Consultant (Ongoing), Grant/Research Support (Ongoing); UCB: Consultant (Ongoing), Grant/Research Support (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing)

  • 2333: Validation of a Corrected Axial Spondyoarthritis Metrology Index in 9 Randomized Clinical Trials

    Tuesday, October 28, 2025
    10:30 AM - 12:30 PM Central Time

    Disclosure(s): AbbVie/Abbott: Consultant (Ongoing), Grant/Research Support (Ongoing); Alfasigma: Consultant (Ongoing), Grant/Research Support (Ongoing); Eli Lilly: Consultant (Ongoing), Grant/Research Support (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Johnson & Johnson: Consultant (Ongoing); Merck/MSD: Consultant (Ongoing); Novartis: Consultant (Ongoing), Grant/Research Support (Ongoing); Pfizer: Consultant (Ongoing), Grant/Research Support (Ongoing); UCB: Consultant (Ongoing), Grant/Research Support (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing)

  • 2332: Development and validation of a Disease Activity index for PSoriatic Arthritis based on 44 joints: DAPSA44

    Tuesday, October 28, 2025
    10:30 AM - 12:30 PM Central Time

    Disclosure(s): AbbVie/Abbott: Consultant (Ongoing), Grant/Research Support (Ongoing); Alfasigma: Consultant (Ongoing), Grant/Research Support (Ongoing); Eli Lilly: Consultant (Ongoing), Grant/Research Support (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Johnson & Johnson: Consultant (Ongoing); Merck/MSD: Consultant (Ongoing); Novartis: Consultant (Ongoing), Grant/Research Support (Ongoing); Pfizer: Consultant (Ongoing), Grant/Research Support (Ongoing); UCB: Consultant (Ongoing), Grant/Research Support (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing)

  • 2635: Differences in structural lesions of the spine between patients with early axSpA and non-axSpA chronic back pain: 2-year results of the SPACE Cohort

    Tuesday, October 28, 2025
    3:30 PM - 3:45 PM Central Time

    Disclosure(s): AbbVie/Abbott: Consultant (Ongoing), Grant/Research Support (Ongoing); Alfasigma: Consultant (Ongoing), Grant/Research Support (Ongoing); Eli Lilly: Consultant (Ongoing), Grant/Research Support (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Johnson & Johnson: Consultant (Ongoing); Merck/MSD: Consultant (Ongoing); Novartis: Consultant (Ongoing), Grant/Research Support (Ongoing); Pfizer: Consultant (Ongoing), Grant/Research Support (Ongoing); UCB: Consultant (Ongoing), Grant/Research Support (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing)